Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology
January 03, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics...
Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company’s Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laboratory Services
December 14, 2022 09:00 ET
|
Avalon GloboCare Corp.
Newly issued preferred stock convertible at a minimum of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Laboratory Services acquisition expected to close within 30...
Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC
December 12, 2022 09:00 ET
|
Avalon GloboCare Corp.
Company Discontinues China Operations, Reducing Cash Burn Encourages Shareholders to Vote in the Upcoming Annual Shareholder Meeting on December 29th FREEHOLD, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE)...
Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”
November 09, 2022 16:00 ET
|
Avalon GloboCare Corp.
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 Symbol Change Better Reflects Avalon’s New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 ...
Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million
November 08, 2022 09:10 ET
|
Avalon GloboCare Corp.
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and...
Avalon GloboCare Receives Allowance for Joint U.S. Patent
September 29, 2022 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today provided an update...
Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society
August 08, 2022 09:00 ET
|
Avalon GloboCare Corp.
Findings support utility of QTY protein code as a novel platform to generate water-soluble proteins for wide spectrum of biomedical applications Reports plans to apply for additional patents...
Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
June 30, 2022 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new...
Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference
May 25, 2022 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David...
Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy
May 18, 2022 09:00 ET
|
Avalon GloboCare Corp.
Goal of Partnership is to expand Avalon’s R&D pipeline to include innovative companion diagnostics in association with the company’s ongoing and future cellular immunotherapy clinical programs ...